SECUKINUMAB

SECUKINUMAB (10425Q)

secukinumab 150 mg/mL injection, 2 x 1 mL pen devices
10425Q
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Continuing treatment, Whole body

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Continuing treatment, Face, hand, foot

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Balance of supply - Continuing treatment, Whole body or Continuing treatment, Face, hand, foot
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 5 DPMQ: $1,336.28 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx

SECUKINUMAB (10494H)

secukinumab 150 mg/mL injection, 2 x 1 mL pen devices
10494H
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Initial 1, Whole body or Face, hand, foot (new patient) or Initial 2, Whole body or Face, hand, foot (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3, Whole body or Face, hand, foot (re-commencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 2 DPMQ: $1,336.28 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx

SECUKINUMAB (10894J)

secukinumab 150 mg/mL injection, 2 x 1 mL pen devices
10894J
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe psoriatic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)

Restriction

Indication: Severe psoriatic arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

Restriction

Indication: Severe psoriatic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 4 Max qty units: 8 # of repeats: 0 DPMQ: $5,165.92 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx

SECUKINUMAB (10899P)

secukinumab 150 mg/mL injection, 2 x 1 mL pen devices
10899P
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe psoriatic arthritis
Treatment phase: Continuing treatment

Restriction

Indication: Severe psoriatic arthritis
Treatment phase: Continuing treatment - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 5 DPMQ: $1,336.28 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx

SECUKINUMAB (10901R)

secukinumab 150 mg/mL injection, 2 x 1 mL pen devices
10901R
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe psoriatic arthritis
Treatment phase: Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 2 DPMQ: $1,336.28 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx

SECUKINUMAB (10910F)

secukinumab 150 mg/mL injection, 2 x 1 mL pen devices
10910F
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Initial treatment - Initial 1, Whole body (new patient)

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Initial treatment - Initial 2, Whole body (change or recommencement of treatment after a break in biological medicine of less than 5 years)

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Initial treatment - Initial 3, Whole body (recommencement of treatment after a break in biological medicine of more than 5 years)

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Initial treatment - Initial 1, Face, hand, foot (new patient)

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Initial treatment - Initial 2, Face, hand, foot (change or recommencement of treatment after a break in biological medicine of less than 5 years)

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Initial treatment - Initial 3, Face, hand, foot (recommencement of treatment after a break in biological medicine of more than 5 years)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 4 Max qty units: 8 # of repeats: 0 DPMQ: $5,165.92 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx

SECUKINUMAB (14146M)

secukinumab 150 mg/mL injection, 2 x 1 mL pen devices
14146M
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Moderate to severe hidradenitis suppurativa
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 5 DPMQ: $1,336.28 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx

SECUKINUMAB (14154Y)

secukinumab 150 mg/mL injection, 2 x 1 mL pen devices
14154Y
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Moderate to severe hidradenitis suppurativa
Treatment phase: Initial treatment - Initial 1 (new patient)

Restriction

Indication: Moderate to severe hidradenitis suppurativa
Treatment phase: Initial treatment - Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years)

Restriction

Indication: Moderate to severe hidradenitis suppurativa
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 4 Max qty units: 8 # of repeats: 0 DPMQ: $5,165.92 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx

SECUKINUMAB (14161H)

secukinumab 150 mg/mL injection, 2 x 1 mL pen devices
14161H
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Moderate to severe hidradenitis suppurativa
Treatment phase: Initial treatment - Initial 1 (new patient)

Restriction

Indication: Moderate to severe hidradenitis suppurativa
Treatment phase: Initial treatment - Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years)

Restriction

Indication: Moderate to severe hidradenitis suppurativa
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 3 DPMQ: $1,336.28 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx

SECUKINUMAB (14164L)

secukinumab 150 mg/mL injection, 2 x 1 mL pen devices
14164L
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Moderate to severe hidradenitis suppurativa
Treatment phase: Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 3 DPMQ: $1,336.28 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx